Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.995
+0.065 (2.22%)
At close: Apr 16, 2026, 4:00 PM EDT
2.990
-0.005 (-0.17%)
After-hours: Apr 16, 2026, 6:27 PM EDT
CNTB Employees
Connect Biopharma Holdings had 64 employees as of December 31, 2025. The number of employees increased by 2 or 3.23% compared to the previous year.
Employees
64
Change (1Y)
2
Growth (1Y)
3.23%
Revenue / Employee
$1,000
Profits / Employee
-$866,875
Market Cap
169.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 64 | 2 | 3.23% |
| Dec 31, 2024 | 62 | -19 | -23.46% |
| Dec 31, 2023 | 81 | -19 | -19.00% |
| Dec 31, 2022 | 100 | -8 | -7.41% |
| Jan 1, 2022 | 108 | 46 | 74.19% |
| Dec 31, 2020 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Replimune Group | 479 |
| Fate Therapeutics | 161 |
| Heron Therapeutics | 128 |
| Agenus | 81 |
| Cartesian Therapeutics | 75 |
| Tenaya Therapeutics | 70 |
| Corbus Pharmaceuticals Holdings | 36 |
| Unicycive Therapeutics | 22 |
CNTB News
- 16 days ago - Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - GlobeNewsWire
- 17 days ago - Connect Biopharma Announces $20.2 Million Private Placement Financing - GlobeNewsWire
- 17 days ago - Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - GlobeNewsWire
- 17 days ago - Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD - GlobeNewsWire
- 5 weeks ago - Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting - GlobeNewsWire
- 6 weeks ago - Connect Biopharma to Present at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 3 months ago - Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026 - GlobeNewsWire